https://oncodesign-services.propulse.dev/cpt_ressource/ 2026-01-29T09:32:33+00:00 https://oncodesign-services.propulse.dev/fr/cpt_ressource/ 2026-01-29T09:32:33+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/life-science/ 2021-06-22T17:23:43+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2006-medaka-simplet-fam53b-belongs-to-a-family-of-novel-vertebrate-genes-controlling-cell-proliferation/ 2021-07-09T09:22:34+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2006-triterpene-saponins-from-schefflera-abyssinica-l-tapondjou-a-c-mitaine-offer-t-miyamoto-h-lerche-j-f-mirjolet-n-guilbaud-m-a-lacaille-dubois-biochem-syst-and-eco-2006-dec-341/ 2021-07-09T09:23:21+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2006-triterpene-saponins-from-eryngium-campestre/ 2021-07-09T09:24:06+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2006-krn951-a-highly-potent-and-selective-inhibitor-of-vascular-endothelial-growth-factor-receptor-tyrosine-kinases-has-anti-tumor-activities-and-affects-functional-vascular-properties/ 2021-07-09T09:24:40+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2007-vegf-kinoid-vaccine-a-therapeutic-approach-against-tumor-angiogenesis-and-metastases-f-haghighi-rad-h-le-buanec-s-paturance-p-larcier-p-genne-b-ryffel-a-bensussan-b-bizzini-r/ 2021-07-09T09:25:25+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2010-preferential-effect-of-synchrotron-microbeam-radiation-therapy-on-intracerebral-9l-gliosarcoma-vascular-networks/ 2021-07-09T09:30:07+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2010-assessment-of-blood-volume-vessel-size-and-the-expression-of-angiogenic-factors-in-two-rat-glioma-models-a-longitudinal-in-vivo-and-ex-vivo-study/ 2021-07-09T09:30:55+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2011-from-a-personal-point-of-view/ 2021-07-09T09:32:37+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2005-pursaethosides-a-e-triterpene-saponins-from-entada-pursaetha/ 2021-07-09T09:34:32+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2005-a-virus-directed-enzyme-prodrug-therapy-vdept-strategy-for-lung-cancer-using-a-cyp2b6-nadph-cytochrome-p450-reductase-fusion-protein/ 2021-07-09T09:35:10+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2005-tumor-penetration-of-gefitinib-iressa-an-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor/ 2021-07-09T09:35:47+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2005-activation-of-gpr54-promotes-cell-cycle-arrest-and-apoptosis-of-human-tumor-cells-through-a-specific-transcriptional-program-not-shared-by-other-gq-coupled-receptors/ 2021-07-09T09:36:31+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2005-role-of-non-invasive-animal-imaging-in-preclinical-anticancer-drug-development-french-review/ 2021-07-09T09:37:17+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2003-characterization-of-human-smg5-7a-a-protein-with-similarities-to-caenorhabditis-elegans-smg5-and-smg7-that-functions-in-the-dephosphorylation-of-upf1/ 2021-07-09T09:37:53+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2003-rationale-supporting-the-use-of-vasoconstrictors-for-intraperitoneal-chemotherapy-with-platinum-derivatives-review/ 2021-07-09T09:38:40+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2003-oncoprotein-expression-of-e6-and-e7-does-not-prevent-5-fluorouracil-5fu-mediated-g1-s-arrest-and-apoptosis-in-5fu-resistant-carcinoma-cell-lines/ 2021-07-09T09:39:45+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2003-specific-recruitment-of-antigen-presenting-cells-by-chemerin-a-novel-processed-ligand-from-human-inflammatory-fluids/ 2021-07-09T09:40:26+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2002-europium-labeled-epidermal-growth-factor-and-neurotensin-novel-probes-for-receptor-binding-studies/ 2021-07-09T09:41:07+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2002-g1-s-but-not-g0-g1cell-fraction-is-related-to-5-fluorouracil-cytotoxicity/ 2021-07-09T09:42:31+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2002-improved-tumor-selectivity-of-radiolabeled-peptides-by-receptor-and-antigen-dual-targeting-in-the-neurotensin-receptor-model/ 2021-07-09T09:43:09+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2002-radiation-could-induce-p53-independent-and-cell-cycle-unrelated-apoptosis-in-5-fluorouracil-radiosensitized-head-and-neck-carcinoma-cells/ 2021-07-09T09:43:57+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2002-antitumor-activity-of-troxacitabine-troxatyl-against-anthracycline-resistant-human-xenografts/ 2021-07-09T09:44:42+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2001-nonsense-mediated-mrna-decay-insights-into-mechanism-from-the-cellular-abundance-of-human-upf1-upf2-upf3-and-upf3x-proteins-review/ 2021-07-09T09:46:08+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2001-modulation-of-apoptosis-by-procaspase-2-short-isoform-selective-inhibition-of-chromatin-condensation-apoptotic-body-formation-and-phosphatidylserine-externalisation/ 2021-07-09T09:46:51+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2001-identification-and-characterization-of-human-orthologues-to-saccharomyces-cerevisiae-upf2-protein-and-upf3-protein-caenorhabditis-elegans-smg-4/ 2021-07-09T09:47:26+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2001-involvement-of-caspase-2-long-isoform-in-fas-mediated-cell-death-of-human-leukemic-cells/ 2021-07-09T09:48:04+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2001-evidence-for-a-pioneer-round-of-mrna-translation-mrnas-subject-to-nonsense-mediated-decay-in-mammalian-cells-are-bound-by-cbp80-and-cbp20/ 2021-07-09T09:48:39+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2001-constitutive-nf-kappab-activity-influences-basal-apoptosis-and-radiosensitivity-of-head-and-neck-carcinoma-cell-lines/ 2021-07-09T09:49:11+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2000-phase-i-study-of-cinchonine-a-multidrug-resistance-reversing-agent-combined-with-the-chvp-regimen-in-relapsed-and-refractory-lymphoproliferative-syndromes/ 2021-07-09T09:50:38+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2000-preclinical-evaluation-of-aromatase-inhibitors-antitumor-activity-review-in-french/ 2021-07-09T09:51:12+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2000-enhanced-targeting-specificity-to-tumor-cells-by-simultaneous-recognition-of-two-antigens/ 2021-07-09T09:51:51+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1999-mdr1-and-thymidylate-synthase-gene-expressions-in-advanced-breast-cancer-relationships-to-p53-mutations-response-to-primary-chemotherapy-and-survival/ 2021-07-09T09:52:27+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1998-thymidylate-synthase-expression-and-activity-relation-to-s-phase-parameters-and-5-fluorouracil-sensitivity/ 2021-07-09T09:53:18+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1998-s9788-modulates-p-gp-and-mrp-mediated-mdr-in-doxorubicin-resistant-mcf7cells/ 2021-07-09T09:53:58+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1998-multidrug-resistance-genes-mrp-and-mdr1-expression-in-small-cell-lung-cancer-xenografts-relationship-with-response-to-chemotherapy/ 2021-07-09T09:54:40+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1997-two-rna-binding-domains-determine-the-rna-binding-specificity-of-nucleolin/ 2021-07-09T09:55:27+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1997-french-multicentric-evaluation-of-mdr1-gene-expression-by-rt-pcr-in-leukemia-and-solid-tumours-standardization-of-rt-pcr-and-preliminary-comparisons-between-rt-pcr-and-immunohistochemistry-in/ 2021-07-09T09:56:06+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/1997-cytoskeleton-alterations-in-mcf7r-a-multidrug-resistant-human-breast-cancer-cell-line/ 2021-07-09T09:56:58+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/our-brand-oncodesign/ 2022-10-17T15:11:23+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/parkinsons-disease-growing-prevalence-and-continued-significant-medical-need/ 2022-10-17T15:11:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/04/parkinson_AdobeStock_123994478-scaled.jpg https://oncodesign-services.propulse.dev/cpt_ressource/2011-imaging-cancer-biomarkers/ 2022-11-04T10:15:34+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/en-conquering-sensitive-cyps-ugts-and-transporters-protein-quantification-with-qtap-analysis/ 2022-11-04T13:03:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/image_Webinar_Conquering_sensitive_CYPs_UGTs_and_transporters_protein_quantification.png https://oncodesign-services.propulse.dev/cpt_ressource/en-cutting-edge-humanized-mouse-models-to-predict-the-patient-response-to-cancer-treatments/ 2022-11-04T13:04:55+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/06/Histology-colitis-model.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-drug-biodistribution-efficacy-how-can-radiolabeling-a-molecule-make-the-difference/ 2022-11-04T13:07:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/12/DRIVE-SM-Banner-website.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-better-predict-the-effect-of-cancer-immunotherapy-tailored-made-humanized-mouse-models-are-the-key-solution/ 2022-11-04T13:08:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/06/Cancer-visuel-accord-SEngine.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-kick-start-the-immune-response-in-anti-tumor-therapy-a-unique-screening-platform-to-identify-icd-inducers/ 2022-11-04T13:11:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_WEbinar_article_Webikeo.png https://oncodesign-services.propulse.dev/cpt_ressource/en-integrating-pharmacology-and-imaging-in-preclinical-oncology-drug-development/ 2022-11-04T13:12:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/WebinarCOVID_website_newspage.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-preclinical-assessment-of-targeted-radionuclide-therapy-a-step-further-toward-precision-medicine/ 2022-11-04T13:15:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/06/Cancer-visuel-accord-SEngine.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-predictive-cancer-models-for-better-precision-medicine/ 2022-11-04T13:16:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/11/visuel-oncologie.jpg https://oncodesign-services.propulse.dev/cpt_ressource/webinaires-cahier-de-vacances-de-lete/ 2022-11-04T13:18:21+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/10/254-Oncodesign-Paris-Antoine-Martel-Photographe.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-pharmaco-imaging-potential-in-translational-research-a-case-study-of-egfr-pet-radiotracer/ 2022-11-04T13:19:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/Cover-Imaging.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-will-present-next-generation-targeted-molecules-for-auto-immune-and-neurodegenerative-diseases-based-on-the-nanocyclix-approach-at-the-9th-drug-discovery-chemistry-conference-in-san-diego/ 2022-11-04T13:52:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/tumor-specific-molecular-changes-in-luminal-b-breast-cancer-patient-derived-xenografts-pdxs-with-acquired-resistance-to-endocrine-treatment/ 2022-11-15T08:52:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/discovery-of-novel-inhibitors-of-pim-1-kinase-enabled-by-generative-ai/ 2022-11-15T08:54:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/microsphere-encapsulated-4oh-tamoxifen-a-new-sustained-release-delivery-system-with-antitumour-activity-against-dmba-induced-mammary-carcinoma-in-sprague-dawley-rats/ 2022-11-15T14:20:52+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/antitumor-activity-study-of-oxaliplatin-combined-with-epinephrine-after-intraperitoneal-or-intratumoral-administration-on-advanced-peritoneal-carcinomatosis-or-subcutaneous-tumor-from-rat-colon-cancer/ 2022-11-15T14:24:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/in-vivo-screening-of-anticancer-agents-for-intratumor-it-treatment-of-human-glioma-in-combination-with-epinephrine-ep/ 2022-11-15T14:25:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/antitumor-activity-study-of-vinorelbine-against-a-human-pc-3-prostate-tumor-xenografted-in-nude-rats/ 2022-11-15T14:25:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/antitumour-pharmacokinetics-and-distribution-studies-of-diflomotecan-bn80915-administered-intravenously-to-nude-rats-xenografted-with-human-nsc-nci-h460-lung-tumour-cells/ 2022-11-15T14:27:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/gene-expression-profile-analysis-of-paclitaxel-induced-changes-in-the-mda-mb231-human-breast-cancer-xenograft-model/ 2022-11-15T14:33:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/evaluation-of-the-bcnu-chemosensitivity-of-a-panel-of-glioma-models-in-relation-with-vessel-size-index-blood-volume-and-diffusion-mr-imaging-parameters/ 2022-11-15T14:34:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/validation-of-tumor-bearing-nude-rat-as-a-model-to-study-anticancer-druf-pharmacokinetic-pharmacodynamic-pk-pd-relationships/ 2022-11-15T14:35:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/assessment-of-the-anti-vascular-activity-of-mn-029-in-calu-6-human-lung-tumors-using-dce-mri-and-flood-mri/ 2022-11-15T14:37:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/comparison-of-6-experimental-models-of-brain-tumors-morphological-and-vascular-characteristics/ 2022-11-15T14:37:44+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/photodynamic-therapy-with-tookad-in-an-orthotopic-human-prostate-cancer-xenografted-in-nude-rat/ 2022-11-15T14:37:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/biological-characterization-and-non-invasive-pet-imaging-explorations-of-lymphatic-dissemination-in-a-human-melanoma-xenograft-model/ 2022-11-15T14:38:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/disseminated-human-hematological-malignancies-xenografted-in-athymic-mice-dedicated-to-targeted-therapies-evaluation/ 2022-11-15T14:38:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/single-low-dose-treatment-of-lymphoma-and-renal-cancer-xenografts-with-human-anti-cd70-antibody-toxin-conjugates-results-in-long-term-cures/ 2022-11-15T14:39:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/identification-by-systematic-in-situ-hybridization-screen-on-medaka-embryos-of-new-genes-as-targets-for-anti-cancer-therapy/ 2022-11-15T14:40:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/intravenous-infusions-of-trin-2755-a-new-alkylating-agent-inhibit-the-growth-of-human-mda-mb-231-breast-tumour-in-nude-rats/ 2022-11-15T14:40:21+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/anticancer-activity-of-mycobacterial-cell-wall-dna-complex-mcc-in-a-model-of-rat-colon-cancer-peritoneal-carcinomatosis/ 2022-11-15T14:40:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/development-of-drug-conjugated-monoclonal-antibodies-against-muc16-for-treatment-of-epithelial-ovarian-cancers/ 2022-11-15T14:40:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/synergistic-anticancer-activity-of-eribulin-plus-palbociclib-in-patient-derived-xenograft-pdx-models-of-er-her2-human-breast-cancer/ 2022-11-15T14:41:02+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/nanocyclix-next-generation-kinase-therapeutics-a-chemocentric-approach-for-the-discovery-of-selective-kinase-inhibitors/ 2022-11-15T14:41:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/novel-fluorescent-probes-evaluated-in-an-orthotopic-pancreatic-pdx-model/ 2022-11-15T14:41:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/nanocyclix-alk2-inhibitors-to-overcome-cancer-induced-anemia/ 2022-11-15T14:41:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2011-modeling-the-sequence-sensitive-gemcitabine-docetaxel-combination-using-the-virtual-tumor/ 2022-11-15T14:46:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2011-dota-conjugated-antibodies-for-scintigraphic-evaluation-of-new-anti-cancer-treatments/ 2022-11-15T14:47:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2011-extensive-use-of-fresh-patient-derived-tumor-samples-for-drug-discovery-and-drug-positioning-in-oncology/ 2022-11-15T14:47:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2011-humanized-scid-mouse-as-tool-for-evaluation-of-b-cell-targeting-therapies/ 2022-11-15T14:48:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-antitumor-activity-of-ep80061-a-small-glyco-drug-in-preclinical-studies/ 2022-11-15T14:51:10+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-preclinical-evaluation-of-indium-111-radiololabeled-trastuzumab-and-pertuzumab-for-her2-positive-breast-cancer-molecular-imaging/ 2022-11-15T15:48:02+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2013-development-program-of-patient-tumor-tissue-bank-to-support-the-drug-and-target-discovery/ 2022-11-15T15:48:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2013-antiprogestin-drug-developement-in-vitro-validation-of-a-potential-clinical-biomarker/ 2022-11-15T15:48:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2013-establishment-and-characterization-of-human-skingraft-model-in-immunodeficient-mice/ 2022-11-15T15:48:10+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2013-use-of-humanized-nog-mice-within-the-pre-clinical-development-of-new-human-specific-therapies/ 2022-11-15T15:48:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2014-biodistribution-and-antitumor-efficacy-study-of-novel-her2-targeting-darpins/ 2022-11-15T15:48:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2014-mouse-renca-renal-cell-carcinoma-syngeneic-model-to-evaluate-efficacy-of-novel-antisense-oligonucleotides-targeting-transforming-growth-factor-beta-tgf-%ce%b2-isoforms/ 2022-11-15T15:48:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2014-pharmacodynamic-evaluation-of-adcc-mediated-effects-in-humanized-il2-or-il15-nog-mice-models/ 2022-11-15T15:48:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2015-evaluation-of-immuno-oncology-related-treatment-in-syngenic-mouse-models/ 2022-11-15T15:49:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2017-antitumor-activity-of-cmp-001-tlr9-agonist-alone-or-combined-with-immune-modulators-in-syngeneic-tumor-modelsdels-of-brain-tumors/ 2022-11-15T15:49:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2017-imodi-initiative-a-novel-holistic-and-integrative-approach-with-patient-derived-tumor-models-against-pancreatic-cancer/ 2022-11-15T15:49:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2017-overcoming-pd-1-targeting-antibody-resistance-using-combination-strategieshuman-lung-tumors-using-dce-mri-and-flood-mri/ 2022-11-15T15:49:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2017-preclinical-proof-of-concept-for-the-first-18f-nanocyclixtki-pet-radiotracer-targeting-activated-egfr-positive-lung-tumors/ 2022-11-15T15:50:00+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/development-of-a-high-throughput-in-vitroscreening-platform-to-identify-novel-inducers-of-immunological-cell-death/ 2022-11-15T15:50:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2018-humanized-mouse-models-for-evaluation-of-cancer-therapies/ 2022-11-15T15:50:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/modulating-t-cell-immunity-in-tumors-by-targeting-tumor-associated-antigens/ 2022-11-15T15:50:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/morab-202-a-folate-receptor-alpha-targeted-antibody-drug-conjugate-shows-a-highly-potent-activity-against-a-panel-of-fr%ce%b1-expressing-tumors/ 2022-11-15T15:51:09+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-april-2016-efficacy-of-pd-1-pd-l1-pathway-disruptors-in-syngeneic-models/ 2022-11-15T15:51:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-april-2016-enhanced-antitumor-activity-achieved-by-combining-the-oncolytic-peptide-ltx-315-with-anti-pd-l1-antibody/ 2022-11-15T15:53:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-april-2016-humanized-mouse-models-for-evaluation-of-cancer-therapies/ 2022-11-15T15:53:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-april-2016-innovative-and-predictive-models-against-cancer-an-imodi-integrative-approach/ 2022-11-15T15:53:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-atlanta-immune-checkpoint-blockade-and-autoimmune-diseases/ 2022-11-15T15:54:00+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-atlanta-induction-of-immunogenic-cell-death-and-enhancement-of-dendritic-cell-function/ 2022-11-15T15:54:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-february-2016-a-novel-holistic-and-integrative-approach-with-patient-derived-tumor-models/ 2022-11-15T15:54:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/adcs-optimization-led-to-a-significant-anti-tumoral-activity-in-lymphoma-and-breast-tumor-xenograft-mouse-models/ 2022-11-15T15:55:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/adcs-optimization-led-to-a-significant-anti-tumoral-activity-in-lymphoma-and-breast-tumor-xenograft-mouse-models-2/ 2022-11-15T15:55:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/bio-it-congress-oncosnipe-al-initiative-designed-to-identify-and-characterize-patients-resistant-or-non-responder-to-cancer-treatments/ 2022-11-15T15:56:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/dce-mri-assessment-of-responses-to-hormonotherapy-in-prenical-breast-and-prostate-cancer-models-in-rats/ 2022-11-15T15:56:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/development-of-a-panel-of-breast-cancer-patient-derived-xenograft-models-pdx-with-estrogen-independence-and-or-acquired-resistance-to-endocrine-treatment/ 2022-11-15T15:57:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/development-of-an-immunogenicity-assay-for-anti-drug-antibody-ada-detection-directed-against-an-oligonucleotide-cpg-d35-using-ecl-technology-msd-2/ 2022-11-15T15:58:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eanm-2017-in-vitro-and-in-vivo-evaluation-of-two-enantiomers-of-nanocyclix-egfr-targeted-pet-radiotracer/ 2022-11-15T15:58:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eanm-2016-pharmacokinetic-of-tumor-fdg-uptake-in-subcutaneous-and-orthotopic-preclinical-models-of-breast-cancer/ 2022-11-15T15:58:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/efmc-asmc17-application-of-the-nanocyclix-technology-to-identify-clinically-relevant-pet-tracerspositive-lung-tumors/ 2022-11-15T15:58:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/efmc-ismc-2018-xxv-efmc-international-symposium-on-medicinal-chemistry/ 2022-11-15T15:58:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eortc-2013-in-vivo-adcc-mediated-antitumor-activity-study-with-new-preclinical-humanized-models/ 2022-11-15T15:58:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eortc-2015-efficacy-of-pd-1-pd-l1-pathway-disruptors-in-syngeneic-models/ 2022-11-15T15:58:48+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eortc-2015-tumor-infiltrating-lymphocytes-as-a-biomarker-of-response-for-ctla-4-targeting-therapies/ 2022-11-15T15:58:56+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eortc-2017-anti-tumour-activity-of-new-antibody-drug-conjugate-adc-with-eribulin-in-triple-negative-breast-cancer-tnbc-patient-derived-xenograft-pdx/ 2022-11-15T15:59:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/eortc-2016-beneficial-outcome-of-combination-therapy-with-4-1bb-mab-targeting-antibody/ 2022-11-15T15:59:10+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/evaluation-of-111in-177lu-antibody-fragments-for-diagnostic-and-therapeutic-purpose/ 2022-11-15T15:59:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/ex-vivo-inhibition-of-lrrk2-phosphorylation-by-a-new-kinase-inhibitor-in-peripheral-blood-cells-of-subjects-with-and-without-g2019s-lrrk2-mutation/ 2022-11-15T15:59:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/identification-and-characterization-of-a-novel-lrrk2-kinase-inhibitor-ods2005294/ 2022-11-15T15:59:39+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/immuno-oncology-summit-europe-development-of-pre-clinical-assays-to-support-drug-discovery-programs-in-immuno-oncology/ 2022-11-15T16:00:56+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/isrs-2017-radiosynthesis-of-the-first-18f-nanocyclix-tki-pet-radiotracer-targeting-activated-egfr-positive-lung-tumors/ 2022-11-15T16:01:00+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/live-biotherapeutic-mrx0518-as-a-modulator-of-immune-responses-in-intestinal-tissue-and-breast-tumor-microenvironment-2/ 2022-11-15T16:01:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/mab-formulation-development-and-stability-studies-through-complementary-and-orthogonal-analytical-methods-2/ 2022-11-15T16:01:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/magnetic-resonance-imaging-of-blood-volume-and-vessel-size-in-a-homogeneously-and-a-heterogeneously-perfused-glioma-model-in-rat-brain-the-impact-of-the-tumor-blodd-volume-status-on-bcnu-treatment/ 2022-11-15T16:02:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/rict-2017-identification-of-potent-alk2-inhibitors-as-potential-treatment-for-stone-man-syndrome/ 2022-11-15T16:03:48+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/widespread-brain-distribution-of-sgsh-enzyme-in-canine-brain-following-white-matter-injection-of-lys-saf302-an-aavrh-10-sgsh-vector/ 2022-11-15T16:04:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/wpc-june-2016-from-syngeneic-to-humanized-mouse-models-addressing-the-needs-for-novel-immunotherapies/ 2022-11-15T16:04:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/wpc-2017-from-syngeneic-to-humanized-murine-models-addressing-the-needs-for-novel-immunotherapies/ 2022-11-15T16:04:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/wpc-november-2016-evaluation-of-immuno-oncology-related-treatments-using-highly-characterized-syngeneic-mouse-tumor-models/ 2022-11-15T16:04:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/wpc-november-2016-immuno-oncology-therapeutics-technological-progression-toward-a-huge-preclinical-challenge-of-humanizing-the-immune-component-in-mice/ 2022-11-15T16:04:39+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/modelling-liver-diseases-from-acute-and-chronic-injury-to-hepatocellular-carcinoma-for-development-of-new-treatments-2/ 2022-11-15T16:05:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-atlanta-customized-methodology-to-investigate-immuno-oncology-drugs-using-humanized-mouse-models/ 2022-11-15T16:06:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/19th-drug-discovery-summit-development-of-a-high-throughput-in-vitro-screening-platform-to-identify-novel-inducers-of-immunological-cell-death/ 2022-11-15T16:07:23+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-pdx-to-correlate-pathways-abnormalities-with-response-to-anti-egfr-therapy/ 2022-11-15T16:07:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-characterization-of-ciea-nog-mice-reconstituted-with-human-cd34-stem-cells-hscs-or-mature-pbmcs/ 2022-11-15T16:07:37+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-enhanced-paclitaxel-delivery-to-tumors-using-a-new-lipid-nanocapsule-based-formulation/ 2022-11-15T16:07:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-measurement-of-tumor-vascular-integrity-changes-in-an-orthotopic-glioma-model-in-rats-induced-by-antiangiogenic-treatment-using-dce-mri/ 2022-11-15T16:07:54+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-evaluation-of-immune-response-in-preclinical-settings/ 2022-11-15T16:09:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2012-development-of-brutons-tyrosine-kinase-btk-inhibitor-ono-wg-307-a-potential-treatment-for-b-cell-malignancies/ 2022-11-15T16:09:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-pet-study-with-11ccholine-and-its-derivates-in-the-human-hormonedependent-prostate-cancer-rat-xenograft-tumor-model-pac120/ 2022-11-15T16:09:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-amuvatinib-mp-470-a-multi-targeted-tyrosine-kinase-inhibitor-and-dna-repair-suppressor-synergizes-with-etoposide-vp-16-in-small-cell-lung-cancer-sclc-cell-lines-and-xenografts/ 2022-11-15T16:09:37+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-in-vivo-characterisation-of-orthotopic-prostate-tumor-and-healthy-rat-prostate-metabolism-using-1h-mrs-at-4-7-t/ 2022-11-15T16:09:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-oncodesign-translational-drug-discovery-process/ 2022-11-15T16:09:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-development-of-a-fully-human-immune-system-in-nod-scid-il2rgamma-nsg-mice-for-oncology-research-purpose/ 2022-11-15T16:09:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/17th-annual-world-preclinical-congress-presentation/ 2022-11-15T16:13:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/17th-annual-world-preclinical-congress-smpt-a-tool-for-translational-research/ 2022-11-15T16:13:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/17th-annual-world-preclinical-congress-humanized-mouse-models-for-evaluation-of-cancer-therapies/ 2022-11-15T16:13:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/17th-annual-world-preclinical-congress-development-of-a-high-throughput-in-vitro-screening-platform-to-identify-novel-inducers-of-immunological-cell-death/ 2022-11-15T16:13:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-the-dual-selective-vegfr-fgfr-kinases-inhibitor-e-3810-decreases-tumor-perfusion-and-inhibits-tumor-growth-an-analyis-using-dynamic-contrast-enhanced-magnetic-resonance-imaging/ 2022-11-15T16:13:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-in-vivo-study-of-serum-cancer-biomarkers-and-pain-induced-bone-metastasis-of-human-prostate-tumor-in-nude-rats/ 2022-11-15T16:13:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-is-there-a-species-specific-uptake-of-11ccholine-and-18ffech-in-xenograft-models-in-prostate-cancer/ 2022-11-15T16:13:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-small-animal-pet-mri-an-in-vivo-study-in-oncology-using-a-u-87-mg-mouse-glioma-model/ 2022-11-15T16:13:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-humanized-mouse-model-for-in-vivo-antibody-dependent-cell-mediated-cytotoxicity-evaluation/ 2022-11-15T16:13:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-dce-mri-as-a-tool-to-detect-tumor-vasculature-normalization-by-e7820-a-novel-angiogenesis-inhibitor/ 2022-11-15T16:13:56+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-the-vegf-antagonist-prs-050-decreases-vascular-permeability-in-tumors-and-inhibits-tumor-growth-an-analysis-using-dynamic-contrast-enhanced-magnetic-resonance-imaging/ 2022-11-15T16:13:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-dds-06e-a-novel-oral-ph-sensitive-micellar-formulation-of-sn38-effect-of-dosing-regimen-on-efficacy-and-tolerability-using-a-human-colon-xenograft-model/ 2022-11-15T16:13:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-cremec-initiative-establishment-and-characterization-of-new-in-vivo-models-of-human-colorectal-cancers/ 2022-11-15T16:14:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2010-cremec-initiative-characterization-of-patient-derived-colorectal-tumor-models-and-correlation-with-patient-profile/ 2022-11-15T16:35:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2009-prostate-cancer-metabolism-assessment-by-proton-magnetic-resonance-spectroscopy-1h-mrs-and-high-resolution-magic-angle-spinning-spectroscopy-1h-hrmas-in-experimental-rat-models/ 2022-11-15T16:35:06+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-enhanced-drug-delivery-to-brain-tumors-with-a-new-paclitaxel-peptide-conjugate/ 2022-11-15T16:35:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-enhanced-efficacy-of-therapy-of-anti-cd20-antibody-with-locked-nucleic-acid-antisense-oligonucleotide-targeting-bcl-2-in-human-burkitts-lymphoma-xenografts/ 2022-11-15T16:35:09+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-the-steroid-sulfatase-inhibitor-bn83495-inhibits-e1s-stimulated-growth-of-dmba-induced-mammary-tumours-in-rat/ 2022-11-15T16:35:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-evaluation-of-pet-tracer-uptake-in-mouse-xenograft-models-of-hormone-dependent-prostate-cancer/ 2022-11-15T16:35:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-evaluation-of-tumor-response-to-carmustine-and-sorafenib-with-magnetic-resonance-imaging-in-an-orthotopic-human-glioblastoma-model-xenografted-in-nude-rats/ 2022-11-15T16:35:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-optimization-of-engraftment-of-human-nk-cells-in-nod-scid-mice/ 2022-11-15T16:35:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-mechanism-of-action-of-a-human-anti-cd70-antibody-mgba-conjugate-and-efficacy-in-a-nude-rat-model-of-renal-carcinoma/ 2022-11-15T16:35:21+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/2008-evaluation-of-early-response-to-temozolomide-and-radiotherapy-with-magnetic-resonance-imaging-and-proton-magnetic-resonance-spectroscopy-in-human-glioma-models-in-nude-rats/ 2022-11-15T16:35:23+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/scientific-posters-aacr-2022/ 2022-11-15T16:44:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-nomination-of-arnaud-lafforgue-as-chief-financial-officer/ 2022-11-16T15:12:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-publication-of-an-abstract-for-the-54th-asco-annual-meeting-in-chicago/ 2022-11-16T15:12:52+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-wins-the-innovation-prize-in-the-cfnews-2018-ma-awards/ 2022-11-16T15:13:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/idmit-inauguration-of-a-new-biology-and-health-research-infrastructure-devoted-to-human-infectious-diseases-and-immunology/ 2022-11-16T15:13:23+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-results-of-the-second-stage-of-its-clinical-study-in-lung-cancer/ 2022-11-16T15:13:39+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-furthers-its-cooperation-with-eisai-started-12-years-ago/ 2022-11-16T15:14:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/precision-medicine-cap-digital-and-medicen-paris-region-team-up-with-oncodesign-servier-and-intersystems-on-hu-precimed/ 2022-11-16T15:14:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/centre-georges-francois-leclerc-presents-the-detailed-results-of-the-first-two-stages-of-its-clinical-study-in-lung-cancer-at-the-eanm-congress/ 2022-11-16T15:14:44+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/service-partnership-agreement-between-oncodesign-and-galderma/ 2022-11-16T15:14:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesigns-oncosnipe-collaborative-programme-receives-e7-7-million-in-support-from-the-investments-for-the-future-programme-operated-by-bpifrance/ 2022-11-16T15:15:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-return-of-research-collaboration-and-option-to-license-rights-for-parkinson-program-from-ipsen/ 2022-11-16T15:15:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/business-update-and-fy-2016-results/ 2022-11-16T15:16:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-presents-its-latest-scientific-developments-at-the-aacr-annual-global-meeting-on-oncology/ 2022-11-16T15:16:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-opens-exclusive-negotiations-with-bertin-pharma-for-the-acquisition-of-service-businesses/ 2022-11-16T15:16:39+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-acquisition-of-bertin-pharmas-pharmaceutical-and-biotech-services-businesses/ 2022-11-16T15:17:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-launches-its-new-website/ 2022-11-16T15:18:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncosnipe-artificial-intelligence-project-officially-launched/ 2022-11-16T15:18:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-positive-results-opening-the-way-for-the-alk1-program-to-advance-to-the-lead-optimization-phase/ 2022-11-16T15:18:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-reports-positive-results-for-its-mnk1-2-program/ 2022-11-16T15:19:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/promising-clinical-results-for-innovative-mutated-anti-egfr-radiotracer-in-patients-with-non-small-cell-lung-cancer/ 2022-11-16T15:19:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-biotechnology-and-bristol-myers-squibb-enter-into-strategic-drug-discovery-collaboration/ 2022-11-16T15:19:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-and-ipsen-enter-into-a-strategic-partnership-in-oncology-and-oncodesign-joins-ipsens-paris-saclay-campus/ 2022-11-16T15:20:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-is-granted-new-patent-protecting-key-molecules-generated-from-its-nanocyclix-technology-platform-for-next-generation-kinase-inhibitors/ 2022-11-16T15:21:02+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-launch-of-its-first-clinical-study-on-a-radiotracer-in-patients-with-non-small-cell-lung-cancer/ 2022-11-16T15:21:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/gsk-and-oncodesign-announce-agreement-for-oncodesigns-acquisition-of-gsks-research-centre-in-france/ 2022-11-16T15:21:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/2017-2020-strategic-plan/ 2022-11-16T15:22:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-wins-the-4th-european-small-and-mid-cap-awards-in-the-rising-star-category-21-11-16-telecharger/ 2022-11-16T15:22:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-signs-additional-2-year-preclinical-research-contract-to-evaluate-antibody-drug-conjugates/ 2022-11-16T15:24:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/ucb-exercises-its-option-to-license-a-program-from-oncodesign-targeting-neurological-diseases/ 2022-11-16T15:25:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-creation-of-its-scientific-advisory-board/ 2022-11-16T15:25:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-pursues-its-strategy-of-expansion-in-north-america/ 2022-11-16T15:26:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-presents-novel-lrrk2-inhibitor-jointly-discovered-with-ipsen-at-the-2015-neurosciences-meeting-in-chicago/ 2022-11-16T15:26:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/preclinical-validation-of-oncodesigns-first-radiotracer-prior-to-human-application/ 2022-11-16T15:26:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-seals-a-major-research-agreement-with-cellectis/ 2022-11-16T15:28:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-third-extension-of-a-research-contract-with-isarna-therapeutics/ 2022-11-16T15:28:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-presents-new-supportive-data-for-its-nanocyclix-based-ripk2-program-for-auto-immune-disease-at-the-10th-drug-discovery-chemistry-conference-in-san-diego-ca/ 2022-11-16T15:29:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/us-oncodesign-has-entered-into-a-services-agreement-with-eisai-to-develop-a-new-personalized-medicine-program-in-earlier-line-metastatic-breast-cancer-treatment/ 2022-11-16T15:30:10+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/parkinsons-disease-servier-and-oncodesign-join-forces-to-investigate-new-line-of-research/ 2022-11-16T15:34:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-reaches-a-key-milestone-in-the-development-of-its-ripk2-program/ 2022-11-16T15:34:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-publication-of-an-article-presenting-promising-results-for-the-treatment-of-stone-man-syndrome-fop/ 2022-11-16T15:34:52+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-selection-of-its-first-in-class-ripk2-inhibitor-drug-candidate-for-auto-immune-and-inflammatory-diseases/ 2022-11-16T15:35:02+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-and-servier-reach-a-key-first-milestone-in-their-strategic-partnership-on-lrrk2-inhibitors-for-parkinsons-disease/ 2022-11-16T15:35:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-creation-of-its-new-artificial-intelligence-business-unit-and-appoints-stephane-gerart-as-its-head/ 2022-11-16T15:35:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-and-hitgen-announce-a-strategic-partnership-in-integrated-drug-discovery-services-idds/ 2022-11-16T15:35:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/intersystems-oncodesign-partner-for-the-optimization-of-data-use-to-enhance-and-accelerate-drug-discovery-processes-in-oncology/ 2022-11-16T15:36:54+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/europe-oncodesign-has-entered-into-a-services-agreement-with-eisai-to-develop-a-new-personalized-medicine-program-in-earlier-line-metastatic-breast-cancer-treatment/ 2022-11-16T15:39:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-discovery-of-new-molecule-inhibitors-of-inflammatory-disease-and-the-publication-of-3-new-patent-applications/ 2022-11-16T15:39:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-bfm-oncodesign-nous-allons-accelerer-nos-programmes-et-nos-partenariats/ 2022-11-16T15:58:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-bfm-oncodesign-souhaite-accelerer-lactivite-de-decouverte/ 2022-11-16T16:00:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/bfm-bourse-oncodesign-un-accord-avec-servier-dans-parkinson-relance-oncodesign-en-bourse/ 2022-11-16T16:00:44+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-biotech-oncodesign-gsk-philippe-genne-decortique-le-deal/ 2022-11-16T16:01:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-biotech-oncodesign-une-plateforme-unique-de-composes-et-de-biomarqueurs/ 2022-11-16T16:01:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-biotech-oncosnipe-un-ultra-generateur-dactivites-pour-oncodesign/ 2022-11-16T16:01:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-biotech-bourse-le-projet-de-biomarqueur-dimagerie-doncodesign-entre-en-phase-clinique/ 2022-11-16T16:01:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/biotech-finances-oncodesign-annee-charniere-avant-un-nouveau-cycle/ 2022-11-16T16:01:54+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/biotech-info-oncodesign-la-medecine-de-precision-en-ligne-de-mire/ 2022-11-16T16:02:06+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/biotechs-3-paris-a-tenter-sans-tarder/ 2022-11-16T16:02:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-boursier-oncodesign-a-remporte-les-4emeeuropean-small-and-mid-cap-awards-categorierising-star/ 2022-11-16T16:03:06+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-boursier-oncodesign-se-lance-en-bourse/ 2022-11-16T16:03:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/boursier-com-oncodesign-atteint-une-etape-determinante-dans-le-developpement-de-son-programme-ripk2/ 2022-11-16T16:03:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-boursorama-interview-de-philippe-genne-pdg-doncodesign/ 2022-11-16T16:03:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-boursorama-oncodesign-arrive-sur-alternext-video/ 2022-11-16T16:03:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-capital-oncodesign-une-nouvelle-biotech-debarque-sur-alternext/ 2022-11-16T16:04:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-cercle-finance-oncodesign-ucb-exerce-son-option-sur-un-programme/ 2022-11-16T16:04:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-boursier-oncodesign-un-nouveau-chapitre-de-lhistoire/ 2022-11-16T16:04:48+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-cercle-finance-oncodesign-vise-40-millions-deuros-de-ca-en-2020/ 2022-11-16T16:08:37+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-france-3-la-societe-oncodesign-lance-son-introduction-en-bourse-video/ 2022-11-16T16:09:06+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-france-3-le-laboratoire-dijonnais-oncodesign-presente-des-nouvelles-molecules-therapeutiques-contre-les-cancers/ 2022-11-16T16:09:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/hybrid-business-model-guarantees-substainable-and-healthy-growth/ 2022-11-16T16:10:02+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/investir-com-oncodesign-a-peut-etre-decouvert-la-molecule-qui-va-lui-faire-retrouver-les-faveurs-de-la-bourse/ 2022-11-16T16:10:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-la-bourse-et-la-vie-philippe-genne-interviewe-par-didier-testot/ 2022-11-16T16:10:23+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-la-tribune-oncodesign-a-la-pointe-de-linnovation-pour-guerir-le-cancer/ 2022-11-16T16:10:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-bien-public-les-dijonnais-doncodesign-vont-entrer-en-bourse/ 2022-11-16T16:10:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-bien-public-mouvements-de-fond-oncodesign-augmente-son-capital/ 2022-11-16T16:10:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-bien-public-oncodesign-en-bourse-cest-fait/ 2022-11-16T16:11:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-journal-de-saone-et-loire-investir-contre-le-cancer-oncodesign-entre-en-bourse/ 2022-11-16T16:11:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-monde-maladies-infectieuses-une-plateforme-dimagerie-de-pointe/ 2022-11-16T16:11:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-point-oncodesign-ucb-acquiert-des-droits-pour-une-selection-de-molecules/ 2022-11-16T16:12:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-revenu-nos-questions-a-philippe-genne-pdg-doncodesign/ 2022-11-16T16:12:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-france-3-bourgogne-la-societe-oncodesign-lance-son-introduction-en-bourse/ 2022-11-16T16:12:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-les-echos-oncodesign-cree-un-site-de-recherche-avec-mispro-a-montreal/ 2022-11-16T16:17:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-les-echos-oncodesign-et-ipsen-sallient-dans-un-partenariat-strategique-en-oncologie/ 2022-11-16T16:17:33+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-les-echos-oncodesign-reprend-le-centre-de-recherche-de-gsk-en-france/ 2022-11-16T16:17:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/les-echos-parkinson-oncodesign-sallie-a-servier-pour-trouver-une-therapie-efficace/ 2022-11-16T16:17:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-les-echos-une-annee-2015-dexcellente-facture/ 2022-11-16T16:18:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-mind-health-oncodesign-a-laffut-dacquisitions-en-bioinformatique/ 2022-11-16T16:18:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-un-accord-avec-servier-dans-parkinson-relance-oncodesign-en-bourse/ 2022-11-16T16:18:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-a-peut-etre-decouvert-la-molecule-qui-va-lui-faire-retrouver-les-faveurs-de-la-bourse/ 2022-11-16T16:18:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-amene-un-derisking-important-et-cela-est-de-plus-en-plus-percu-par-les-investissseurs/ 2022-11-16T16:19:00+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-atteint-une-etape-determinante-dans-le-developpement-de-son-programme-ripk2/ 2022-11-16T16:19:14+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-annee-charniere-avant-un-nouveau-cycle/ 2022-11-16T16:19:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/parkinson-oncodesign-sallie-a-servier-pour-trouver-une-therapie-efficace/ 2022-11-16T16:19:56+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-parresia-lintelligence-artificielle-au-service-de-la-medecine-de-precision/ 2022-11-16T16:20:14+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-retrouvez-linterview-de-philippe-genne-lors-du-salon-actionaria-2015/ 2022-11-16T16:20:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/servier-et-oncodesign-ciblent-la-progression-de-la-maladie-de-parkinson/ 2022-11-16T16:21:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/servier-et-oncodesign-sallient-pour-explorer-une-nouvelle-piste-de-recherche-dans-la-maladie-de-parkinson/ 2022-11-16T16:22:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-traces-ecrites-oncodesign-lance-aujourdhui-a-dijon-son-entree-en-bourse-sur-le-marche-alternext-a-paris/ 2022-11-16T16:22:55+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/ifn-gamma-au-rich-element-removal-promotes-chronic-ifn-gamma-expression-and-autoimmunity-in-mice/ 2022-11-16T16:27:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1.png https://oncodesign-services.propulse.dev/cpt_ressource/biopharma-dealmakers-macrocycle-discovery-complements-a-robust-preclinical-program/ 2022-11-16T16:28:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1.png https://oncodesign-services.propulse.dev/cpt_ressource/2013-integrated-pet-mri-in-preclinical-studies-state-of-the-art/ 2022-11-16T16:29:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-ehden-certified-sme/ 2022-11-18T12:42:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/EHDEN_Logo_JPG.jpg https://oncodesign-services.propulse.dev/cpt_ressource/find-out-how-we-built-our-logo/ 2022-11-18T12:43:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Batiment-ODS-Dijon-e1672739033194.jpg https://oncodesign-services.propulse.dev/cpt_ressource/brand-new-logo-for-oncodesign/ 2022-11-18T12:43:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Batiment-ODS-Dijon-e1672739033194.jpg https://oncodesign-services.propulse.dev/cpt_ressource/pharmacokinetic-and-biodistribution-of-formatted-affimer-biotherapeutics-targeting-pd-l1/ 2022-11-18T13:21:55+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/abzena-alira-health-and-oncodesign-launch-drive-biologics-to-support-access-to-specialist-services/ 2022-11-29T10:46:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/02/banner-header-menu-BU-Service.png https://oncodesign-services.propulse.dev/cpt_ressource/sengine-precision-medicine-and-oncodesign-announce-collaboration-agreement-for-the-discovery-of-new-personalized-cancer-treatment-for-aggressive-and-untreatable-tumors/ 2022-11-29T10:46:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/11/CP-Brevet-ODS101-carre-website.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-strengthens-the-intellectual-property-of-ods-101-in-treating-inflammatory-bowel-disease/ 2022-11-29T10:46:55+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/11/CP-Brevet-ODS101-banner-website.jpg https://oncodesign-services.propulse.dev/wp-content/uploads/2021/11/Cycle-de-vie-brevet-EN-2.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-has-appointed-karine-lignel-as-group-chief-development-officer/ 2022-11-29T10:46:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/Header-banner-Ressource-CP-Karine-Lignel.png https://oncodesign-services.propulse.dev/cpt_ressource/en-oncodesign-and-tiumbio-sign-collaboration-agreement-for-rd-of-fibrosis-drug-candidates/ 2022-11-29T10:47:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/Concept-Handshake-business-collaboratin-AdobeStock_418207423-scaled.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-concludes-a-long-term-service-based-partnership-with-erytech-in-oncology/ 2022-11-29T10:47:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/press-release-oncodesign-provides-an-update-on-its-progress-on-ripk2/ 2022-11-29T15:20:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-drug-discovery-cooperation-with-viratherapeutics-a-boehringer-ingelheim-subsidiary/ 2022-11-29T15:24:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-obtains-e15-9-million-of-non-dilutive-financing-in-the-form-of-a-state-guaranteed-loan-within-the-context-of-the-covid-19-pandemic/ 2022-11-29T15:24:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-a-capital-increase-reserved-for-the-companys-management-committee/ 2022-11-29T15:24:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-appointment-of-aline-aubertin-as-an-independent-director-of-the-board-of-directors/ 2022-11-29T15:25:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-covalab-chematech-and-abx-cro-launch-drive-mrt/ 2022-11-29T15:25:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/SOLO-Pharmaco-imaging-e1672738904766.png https://oncodesign-services.propulse.dev/wp-content/uploads/2021/07/DRIVE-MRT-overview-CP-1556-EN.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-launches-its-new-drive-mrt-service-offer-in-partnership-with-covalab-chematech-and-abx-cro/ 2022-11-29T15:25:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/SOLO-Pharmaco-imaging-e1672738904766.png https://oncodesign-services.propulse.dev/cpt_ressource/en-parkinsons-disease-servier-and-oncodesign-announce-the-selection-of-a-preclinical-candidate/ 2022-11-29T15:25:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/11/CP-Brevet-ODS101-carre-website.jpg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-atlanta-targeted-external-or-internal-radiotherapy-in-combination-with-immunotherapies-and-companion-imaging-diagnostics/ 2022-11-29T15:28:21+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/qtap-analysis-transporters-validation-in-vitro-blood-brain-barrier-model/ 2022-12-02T12:41:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/bioanalytical-challenges-with-biochaperone-bc-structures/ 2022-12-02T12:46:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/boursier-com-oncodesign-amene-un-derisking-important-et-cela-est-de-plus-en-plus-percu-par-les-investissseurs/ 2022-12-06T09:41:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/an-evaluation-of-2-deoxy-2-18ffluoro-d-glucose-and-3-deoxy-3-18f-fluorothymidine-uptake-in-human-tumor-xenograft-models/ 2022-12-26T14:42:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1.png https://oncodesign-services.propulse.dev/cpt_ressource/2008-integrating-pharmacology-and-imaging-in-preclinical-oncology-drug-development/ 2022-12-26T14:48:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1.png https://oncodesign-services.propulse.dev/cpt_ressource/the-general-meeting-of-oncodesign-authorises-the-allocation-of-opm/ 2023-01-24T16:50:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/Header-Investor-Day-2021.jpg https://oncodesign-services.propulse.dev/cpt_ressource/eres-iv-acquires-a-majority-stake-in-oncodesign-services/ 2023-04-06T06:59:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/where-to-meet-oncodesign-services-march-2023/ 2023-04-18T08:32:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/02/IMG_AdobeStock_254779498.jpeg https://oncodesign-services.propulse.dev/wp-content/uploads/2022/11/oncodesign-contactez-nous_blue-1024x280.jpg https://oncodesign-services.propulse.dev/cpt_ressource/liposomal-irinotecan-xenograft-models-pancreatic-cancer/ 2023-05-22T10:12:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Scientific_publication_AdobeStock_111385963-374-374-scaled-1.png https://oncodesign-services.propulse.dev/cpt_ressource/gut-microbes-study/ 2023-05-22T10:22:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Blog-Gut-microbes.png https://oncodesign-services.propulse.dev/cpt_ressource/covalent-binders/ 2023-05-25T08:33:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/blog_benzoxaborole-1.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-veritas-in-silico-business-cooperation/ 2023-06-08T14:07:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/Banniere-siteweb-3.png https://oncodesign-services.propulse.dev/cpt_ressource/covalent-drugs-potential-benzoxaboroles/ 2023-06-19T12:17:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/blog_benzoxaborole-e1683819577646.png https://oncodesign-services.propulse.dev/cpt_ressource/oncology-drug-development-3d-cell-models/ 2023-09-19T06:00:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/08/Image1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2014-pharmaco-imaging-study-of-the-effects-of-debio1143-a-new-orally-available-iap-inhibitor-in-a-triple-negative-breast-cancer-model/ 2023-10-13T13:40:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/cadd-computer-tools-and-chemists-combine-to-make-better-drug-leads/ 2023-11-28T14:59:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/07/Bannieres-Ressources-e1694523394505.jpg https://oncodesign-services.propulse.dev/cpt_ressource/2010-characterization-of-tumor-angiogenesis-in-rat-brain-using-iron-based-vessel-size-index-mri-in-combination-with-gadolinium-based-dynamic-contrast-enhanced-mri/ 2023-11-28T15:20:59+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2010-skh-1-mouse-skin-painting-a-short-term-assay-to-evaluate-the-tumorigenic-activity-of-cigarette-smoke-condensate/ 2023-11-28T15:21:45+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/2007-saponins-from-the-roots-of-nylandtia-spinosa/ 2023-11-28T15:25:42+00:00 https://oncodesign-services.propulse.dev/cpt_ressource/fr-le-figaro-oncodesign-un-modele-a-part-parmi-les-biotechs/ 2023-12-06T15:52:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-tout-sur-mes-finances-oncodesign-introduction-en-bourse-dune-biotech-originale/ 2023-12-06T15:53:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-tout-sur-mes-finances-oncodesign-premiere-ipo-eligible-au-pea-pme/ 2023-12-06T15:54:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/fr-tout-sur-mes-finances-oncodesign-succes-de-lipo-sur-alternext-prix-fixe-a-734-euros/ 2023-12-06T15:54:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/Bannieres-Ressources.png https://oncodesign-services.propulse.dev/cpt_ressource/why-you-should-consider-tumor-microenvironment-for-cancer-therapy/ 2023-12-06T16:03:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/06/AdobeStock_305639707.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/preclinical-evaluation-of-chimpanzee-adenovirus-vector/ 2023-12-26T14:54:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/translational-pharmacology-supporting-biologics-development-in-oncology/ 2023-12-26T15:10:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Banner-poster-Drive-biologics-1.png https://oncodesign-services.propulse.dev/cpt_ressource/lewis-acid-catalyzed-chemoselective-and-regioselective-epoxide-ring-opening-with-sulfoximines/ 2023-12-26T15:11:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/09/Banner-poster-EFMC-V2.jpg https://oncodesign-services.propulse.dev/cpt_ressource/in-vivo-pk-pd-profile-of-compound-a/ 2023-12-26T15:15:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/lead-optimization-of-radiopharmaceuticals-for-molecular-radiotherapy-and-preclinical-evaluation/ 2023-12-26T15:17:23+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/mouse-models-of-hepatocellular-carcinoma/ 2023-12-26T15:18:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/structure-based-design-of-small-macrocyclic-cdk9-degraders-as-chemical-biology-tools-and-beyond/ 2023-12-26T15:22:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/animal-models-for-novel-therapies-on-fibrosis-and-nash/ 2023-12-26T15:22:54+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/steps-from-discovery-to-development-novel-biological-entities/ 2024-01-04T13:34:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/simultaneous-18f-fdg-pet-mr-imaging-metastases-identification/ 2024-01-04T13:34:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/oncotam-a-comprehensive-preclinical-platform-to-explore-macrophages/ 2024-01-04T13:35:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/antitumor-activity-comparison-of-two-somatostatin-receptor-ligands-radiolabeled/ 2024-01-04T13:35:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/new-oncology-target-identification-validation-platform-combining-artificial-intelligence-preclinical-pharmacology/ 2024-01-04T13:36:21+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/using-individual-or-a-consortium-of-bacteria-for-immuno-oncology-research/ 2024-01-05T14:32:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/pkhb1-a-thrombospondin-1-peptide-mimic-induces-anti-tumor-effect-through-immunogenic-cell-death-induction-in-breast-cancer-cells/ 2024-01-11T16:26:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/leucettinibs-a-class-of-dyrk-clk-kinase-inhibitors-inspired-by-the-marine-sponge-natural-product-leucettamine-b/ 2024-01-11T16:27:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/rheniumi-diselenoether-compound-significantly-decreased-viral-load-sars-cov-2-infected-pulmonary-cells/ 2024-01-11T16:27:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/comparative-efficacy-and-selectivity-of-pharmacological-inhibitors-of-dyrk-and-clk-protein-kinases/ 2024-01-11T16:28:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/calciumii-catalyzed-chemoselective-and-regioselective-epoxide-ring-opening-with-nh-sulfoximines/ 2024-01-12T15:33:55+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/intranasal-delivery-of-a-chimpanzee-adenovirus-vector-expressing-a-pre-fusion-spike-bv-adcov-1-protects-golden-syrian-hamsters-against-sars-cov-2-infection/ 2024-01-12T15:34:14+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/18ffmiso-pet-ct-imaging-of-hypoxia-as-a-non-invasive-biomarker-of-disease-progression-and-therapy-efficacy-in-a-preclinical-model-of-pulmonary-fibrosis-comparison-with-the-18ffdg-pet-ct-approach/ 2024-01-12T15:34:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/synergistic-interferon-alpha-based-combinations-for-treatment-of-sars-cov-2-and-other-viral-infections/ 2024-01-12T15:34:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncosnipe-study-protocol-a-study-of-molecular-profiles-associated-with-development-of-resistance-in-solid-cancer-patients/ 2024-01-12T15:34:54+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/development-of-small-macrocyclic-kinase-inhibitors/ 2024-01-12T15:35:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/exosting-an-extracellular-vesicle-loaded-with-sting-agonists-promotes-tumor-immune-surveillance/ 2024-01-12T15:35:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/exosome-mediated-genetic-reprogramming-of-tumor-associated-macrophages-by-exoaso-stat6-leads-to-potent-monotherapy-antitumor-activity/ 2024-01-12T15:35:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/ifn-gamma-au-rich-element-removal-promotes-chronic-ifn-gamma-expression-and-autoimmunity-in-mice-2/ 2024-01-12T15:35:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/in-vivo-inhibition-of-ripk2-kinase-alleviates-inflammatory-disease/ 2024-01-12T15:35:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/steroidal-saponins-from-dioscorea-preussii/ 2024-01-12T15:35:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/negative-impact-of-total-body-irradiation-on-the-antitumor-activity-of-rhenium-i-diselenoether/ 2024-01-12T15:38:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/discovery-of-a-9-mer-cationic-peptide-ltx-315-as-a-potential-first-in-class-oncolytic-peptide/ 2024-01-12T15:39:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/near-infrared-emitting-bodipy-trisdota111in-as-a-monomolecular-multifunctional-imaging-probe-from-synthesis-to-in-vivo-investigations/ 2024-01-12T15:39:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/chemotherapy-resistant-human-acute-myeloid-leukemia-cells-are-not-enriched-for-leukemic-stem-cells-but-require-oxidative-metabolism/ 2024-01-12T15:39:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/pdx-mi-minimal-information-for-patient-derived-tumor-xenograft-models/ 2024-01-12T15:39:33+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/nuclear-imaging-study-of-the-pharmacodynamic-effects-of-debio-1143-an-antagonist-of-multiple-inhibitor-of-apoptosis-proteins-iaps-in-a-triple-negative-breast-cancer-model/ 2024-01-12T15:39:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/unraveling-the-interaction-between-carboxylesterase-1c-and-the-antibody-drug-conjugate-syd985-improved-translational-pk-pd-by-using-ces1c-knockout-mice/ 2024-01-12T15:39:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/broad-spectrum-preclinical-antitumor-activity-of-eribulin-halaven-combination-with-anticancer-agents-of-differing-mechanisms/ 2024-01-12T15:40:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/radiolabeled-fab2-cetuximab-for-theranostic-purposes-in-colorectal-and-skin-tumor-bearing-mice-models/ 2024-01-12T15:40:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/homotrimerization-approach-in-the-design-of-thrombospondin-1-mimetic-peptides-with-improved-potency-in-triggering-regulated-cell-death-of-cancer-cells/ 2024-01-12T15:40:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/development-of-macrocycle-kinase-inhibitors-for-alk2-using-fibrodysplasia-ossificans-progressiva-derived-endothelial-cells/ 2024-01-12T15:41:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/g-protein-coupling-of-adhesion-gpcrs-adgre2-emr2-and-adgre5-cd97-and-activation-of-g-protein-signalling-by-an-anti-emr2-antibody/ 2024-01-12T15:41:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/nafamostat-interferon-%ce%b1-combination-suppresses-sars-cov-2-infection-in-vitro-and-in-vivo-by-cooperatively-targeting-host-tmprss2/ 2024-01-12T15:41:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/single-dose-pharmacokinetics-of-intravenous-34-dihydroxyphenylacetic-acid-and-3-hydroxyphenylacetic-acid-in-rats/ 2024-01-12T15:41:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/antitumor-activity-of-eribulin-after-fulvestrant-plus-cdk4-6-inhibitor-in-breast-cancer-patient-derived-xenograft-models/ 2024-01-12T15:42:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/exploring-the-complementarity-of-pancreatic-ductal-adenocarcinoma-preclinical-models/ 2024-01-12T15:42:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/inhibiting-endothelial-cell-function-in-normal-and-tumor-angiogenesis-using-bmp-type-i-receptor-macrocyclic-kinase-inhibitors/ 2024-01-12T15:42:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/antitumor-activity-study-of-vinflunine-against-a-human-small-cell-lung-tumor-xenografted-in-nude-rats/ 2024-01-12T15:42:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/human-ace2-peptide-mimics-block-sars-cov-2-pulmonary-cells-infection/ 2024-01-12T15:42:55+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1989-serum-concentration-of-amiodarone-required-for-an-in-vivo-modulation-of-anthracycline-resistance/ 2024-01-12T15:46:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1990-f11c-antigen-a-membrane-marker-able-to-distinguish-two-regressive-and-progressive-variants-from-a-rat-colon-adenocarcinoma/ 2024-01-12T15:47:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1990-mechanism-of-resistance-of-confluent-human-and-rat-colon-cancer-cells-to-anthracyclines-alteration-of-drug-passive-diffusion/ 2024-01-12T15:48:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1992-cinchonine-a-potent-efflux-inhibitor-to-circumvent-anthracycline-resistance-in-vivo/ 2024-01-12T15:48:31+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1992-histological-reactivity-of-monoclonal-antibody-against-rat-colon-cancer-cells-on-human-and-rat-normal-gut-and-colonic-tumors/ 2024-01-12T15:48:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1992-chimiotherapie-experimentale-de-carcinomatose-peritoneale-dorigine-colique-chez-le-rat-fr/ 2024-01-12T15:49:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1992-confluence-dependent-resistance-in-human-colon-cancer-cells-role-of-reduced-drug-accumulation-and-low-intrinsic-chemosensitivity-of-resting-cells/ 2024-01-12T15:49:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1993-mdr-1-gene-expression-and-villin-synthesis-in-a-colon-cancer-cell-line-differentiated-by-sodium-butyrate/ 2024-01-12T15:50:10+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1994-confluence-dependent-resistance-to-doxorubicin-and-e-cadherin-expression-in-murine-mammary-cells/ 2024-01-12T15:50:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1994-mitoxantrone-aracytine-avec-ou-sans-quinine-dans-le-traitement-des-leucemies-aigues-refractaires-ou-en-rechute-fr/ 2024-01-12T15:51:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1994-deleterious-effect-of-serum-proteins-on-the-amphotericin-b-induced-potentiation-of-cisplatin-in-human-colon-cancer-cells/ 2024-01-12T15:51:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1994-liposomal-mitoxantrone-for-the-local-treatment-of-peritoneal-carcinomatosis-induced-by-colon-cancer-cells-in-mouse/ 2024-01-12T15:52:00+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1994-comparative-effects-of-quinine-and-cinchonine-in-reversing-multidrug-resistance-on-human-leukemic-cell-line-k562-adm/ 2024-01-12T15:52:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1995-adding-a-reverser-verapamil-to-combined-chemotherapy-overrides-resistance-in-small-cell-lung-cancer-xenografts/ 2024-01-12T15:52:50+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1995-cellular-pharmacology-of-azatoxins-topoisomerase-ii-and-tubulin-inhibitors-in-p-glycoprotein-positive-and-negative-cell-lines/ 2024-01-12T15:53:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1995-circumvention-of-confluence-dependent-resistance-in-a-human-multidrug-resistant-colon-cancer-cell-line/ 2024-01-12T15:53:37+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1995-the-role-of-cell-regulation-and-apoptosis-triggering-in-determining-the-sensitivity-of-leukemic-cells-to-topoisomerase-i-and-ii-inhibitors/ 2024-01-12T15:53:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1995-cinchonine-administrated-per-os-efficient-to-circumvent-p-glycoprotein-mediated-multidrug-resistance-in-vivo/ 2024-01-12T15:54:22+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1997-pretargeted-radioimmunotherapy-using-131-i-labelled-bivalent-hapten-bearing-peptides/ 2024-01-12T15:55:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/1997-bivalent-hapten-bearing-peptides-designed-for-iodine-131-pretargeted-radioimmunotherapy/ 2024-01-12T15:55:27+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/challenges-and-perspectives-in-the-preclinical-development-of-therapeutic-agents-against-lung-fibrosis/ 2024-01-18T13:51:37+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/04/Design-sans-titre-5.jpg https://oncodesign-services.propulse.dev/cpt_ressource/long-covid/ 2024-01-22T15:00:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/06/25.jpg https://oncodesign-services.propulse.dev/cpt_ressource/doublet-triplet-combinations-eribulin-fulvestrant-and-palbociclib-preclinical-breast-cancer-models/ 2024-01-30T09:42:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-looks-to-the-future/ 2024-01-30T10:50:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/11/Batiment-ODS-Dijon-e1672739033194.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncolytic-virus-research/ 2024-01-30T10:51:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/12/IMG-PR-ViraT_ODS.jpg https://oncodesign-services.propulse.dev/cpt_ressource/navigating-from-molecules-to-medicines-chemistry-department/ 2024-01-30T10:52:02+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/4.jpg https://oncodesign-services.propulse.dev/cpt_ressource/breast-cancer-awareness-month/ 2024-01-30T10:52:38+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/10/31.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-receives-global-excellence-awards/ 2024-01-30T12:56:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/07/Post-Linkedin-23.png https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-appoints-eftychia-koumarianou/ 2024-01-30T12:57:49+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/28.jpg https://oncodesign-services.propulse.dev/cpt_ressource/generative-ai-empowers-search-pim1-kinase-inhibitors/ 2024-01-30T12:59:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-sa-is-now-oncodesign-services-sa/ 2024-01-30T13:02:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/01/Batiment-ODS.jpg https://oncodesign-services.propulse.dev/cpt_ressource/euronext-paris-authorises-the-listing-of-opm-shares/ 2024-01-30T13:03:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/07/PressRealase_July2021.png https://oncodesign-services.propulse.dev/cpt_ressource/servier-exercises-the-exclusive-worldwide-license-option-of-their-collaboration-program-lrrk2/ 2024-01-30T13:04:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/CP-Servier-Oncodesign-Parkinson-2021-scaled.jpg https://oncodesign-services.propulse.dev/cpt_ressource/opm-and-servier-announce-a-strategic-collaboration-to-discover-new-therapeutic-targets-for-pancreatic-cancer-treatment/ 2024-01-30T13:04:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/Concept-Handshake-business-collaboratin-AdobeStock_418207423-scaled.jpg https://oncodesign-services.propulse.dev/cpt_ressource/comparison-of-the-anti-tumour-activity-of-the-somatostatin-receptor-sst-antagonist-177lulu-satoreotide-tetraxetan-and-the-agonist-177lulu-dota-tate-in-mice-bearing-ar42j-sst2-positive-tumours/ 2024-01-30T13:05:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/09/Sans-titre-1556-x-425-px-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-announces-the-separation-of-its-two-business-lines-service-and-biotech/ 2024-01-30T13:06:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/notre-management.jpg https://oncodesign-services.propulse.dev/cpt_ressource/in-vitro-pharmacological-profile-of-compound-a/ 2024-01-30T13:06:33+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/advancing-drug-discovery-through-3d-cell-models/ 2024-02-05T11:04:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/combitherapy-in-preclinical-breast-cancer-hr-her2-models/ 2024-02-05T13:08:33+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Vignettes-ressources.jpg https://oncodesign-services.propulse.dev/cpt_ressource/ibd-case-study/ 2024-02-20T16:06:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/02/Colitis.jpg https://oncodesign-services.propulse.dev/wp-content/uploads/2023/02/timeline-email_INPACT.png https://oncodesign-services.propulse.dev/cpt_ressource/phinc-development-and-oncodesign-services/ 2024-02-22T09:13:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Sans-titre-1200-x-628-px.jpg https://oncodesign-services.propulse.dev/cpt_ressource/advancing-pulmonary-fibrosis-preclinical-readouts-in-mice-models/ 2024-03-12T07:00:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Banniere-siteweb-3.jpg https://oncodesign-services.propulse.dev/cpt_ressource/meet-pierre/ 2024-03-27T09:37:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/03/Post-Linkedin-6.jpg https://oncodesign-services.propulse.dev/cpt_ressource/examples-of-translational-preclinical-models-to-mimic-cancer-drug-resistance/ 2024-04-08T06:00:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/evaluation-of-checkpoint-inhibitor-efficacy-in-a-humanized-immune-system-mouse-model-lacking-murine-fc-gamma-receptors/ 2024-04-08T07:14:34+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/antitumor-activity-mtl-004-following-intra-cranial-administration-to-post-resection-glioblastoma-bearing-rats/ 2024-04-08T07:15:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/new-technologies-and-capabilities-supporting-the-development-of-novel-molecular-radiotherapy-agents/ 2024-04-22T08:42:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/gut-microbiome-integration-in-drug-discovery-and-development-of-small-molecules/ 2024-04-22T14:38:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Paper-Highlight-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-acquires-zobio/ 2024-04-29T13:41:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/Bannieres-Ressources-17-1.png https://oncodesign-services.propulse.dev/cpt_ressource/next-frontier-in-cancer-deep-dive-into-oncolytic-viruses/ 2024-05-06T08:35:48+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/04/Bannieres-Ressources-3.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-announce-access-to-imaginabs-cd8-immunopet-technology/ 2024-05-24T13:22:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/06/Plan-de-travail-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-zobio-itw/ 2024-05-24T13:26:44+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/1-photo-ajoutee-1-1-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/international-day-women-in-science/ 2024-05-24T13:47:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/02/Bannieres-Ressources-5.png https://oncodesign-services.propulse.dev/cpt_ressource/chemical-biochemical-cellular-physiological-characterization-leucettinib-21-down-syndrome-alzheimers-disease-drug-candidate/ 2024-06-26T07:32:06+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/06/Paper-Highlight-2.jpg https://oncodesign-services.propulse.dev/cpt_ressource/meeting-patrick-jimonet/ 2024-07-04T14:11:18+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/04/Bannieres-Ressources-4.jpg https://oncodesign-services.propulse.dev/cpt_ressource/targeted-rna-degradation-principle-therapeutic-promises/ 2024-07-29T13:06:04+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/Banniere-siteweb-3.png https://oncodesign-services.propulse.dev/cpt_ressource/development-of-an-immunogenicity-assay-for-anti-drug-antibody-ada/ 2024-07-31T14:41:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-2015-in-vivo-tk-nog-liver-humanized-model-to-predict-patient-pharmacological-profile-of-anti-cancer-agents/ 2024-07-31T14:42:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/07/AdobeStock_170028715-scaled-e1672739064803.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/en-supporting-your-immuno-onco-drug-discovery-programs-from-hit-identification-to-candidate-selection/ 2024-07-31T15:54:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/WebinarCOVID_website_newspage.jpg https://oncodesign-services.propulse.dev/cpt_ressource/immunogenicity-and-efficacy-of-vla2001-vaccine-against-sars-cov-2-infection-in-male-cynomolgus-macaques/ 2024-07-31T16:02:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/04/Paper-Highlight-10-1.png https://oncodesign-services.propulse.dev/cpt_ressource/meet-mylinda-in-vitro-study-research-technician/ 2024-08-01T06:49:44+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/05/Bannieres-Ressources-9.jpg https://oncodesign-services.propulse.dev/cpt_ressource/incendiary-by-nature-connecting-inflammation-and-cancer-complexity/ 2024-08-01T09:24:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/03/31.png https://oncodesign-services.propulse.dev/cpt_ressource/how-to-target-rna-modulation-with-small-molecule/ 2024-08-22T09:09:52+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/03/Banniere-siteweb-10.jpg https://oncodesign-services.propulse.dev/cpt_ressource/kinase-inhibitors-inflammatory-diseases-preclinical-development/ 2024-08-22T09:11:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/06/023b7e.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-preclinical-models-for-the-identification-of-chemotherapy-predictive-signatures-in-pancreatic-cancer/ 2024-08-22T09:13:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/83_1mb.jpg https://oncodesign-services.propulse.dev/cpt_ressource/fragment-based-drug-discovery-hitting-targets-using-the-right-chemistry-and-expertise-alliances/ 2024-08-22T09:14:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/10/banniere-webinar-fbdd-3.png https://oncodesign-services.propulse.dev/cpt_ressource/the-game-changing-role-of-artificial-intelligence-in-drug-discovery/ 2024-10-10T15:27:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/37.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncology-cro-of-the-year-2024-france/ 2024-10-25T10:03:11+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/10/Page-Onco-Award-V3.png https://oncodesign-services.propulse.dev/cpt_ressource/medicinal-chemists-insights-into-the-microbiome/ 2024-11-27T13:04:44+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/11/Bannieres-Ressources-_1556-x-425-px_-1.webp https://oncodesign-services.propulse.dev/cpt_ressource/bio-us-2024/ 2024-12-31T12:52:03+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/05/Bannieres-Ressources-8.jpg https://oncodesign-services.propulse.dev/cpt_ressource/how-oncodesign-services-contributed-to-the-development-of-a-new-covid-19-vaccine/ 2024-12-31T12:55:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/04/Bannieres-Ressources-6.jpg https://oncodesign-services.propulse.dev/cpt_ressource/eortc-2023-ods/ 2024-12-31T13:07:07+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/24.jpg https://oncodesign-services.propulse.dev/cpt_ressource/aacr-annual-meeting-2023-2/ 2024-12-31T14:10:12+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/03/Bannieres-Ressources-10.png https://oncodesign-services.propulse.dev/cpt_ressource/why-preclinical-cancer-models-fails-clinic/ 2025-02-25T16:30:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/01/IMG_blood-cells-attacking-a-cancer-cell-AdobeStock_224205869.jpg https://oncodesign-services.propulse.dev/cpt_ressource/five-reasons-why-you-should-switch-to-digital-pcr-dpcr/ 2025-03-03T13:17:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/05/banner-dpcr-2.jpg https://oncodesign-services.propulse.dev/cpt_ressource/capturing-out-of-range-target-engagement-kinetics/ 2025-03-04T14:12:39+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/03/3096.jpg https://oncodesign-services.propulse.dev/cpt_ressource/publication-the-nature-of-nanodisc-lipids-influences-fragment-based-drug-discovery-results/ 2025-03-28T10:43:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/03/NJ_4575_1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/discovering-molecular-glues-using-cooperativity-based-approach/ 2025-04-16T08:35:45+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/04/Design-sans-titre-2.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncodesign-services-appoints-aidan-synnott-as-ceo-to-enhance-strategic-drug-discovery-partnerships/ 2025-04-23T13:18:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/Banniere-siteweb-2-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/radioligand-binding-assays-a-lost-art-in-drug-discovery/ 2025-04-24T10:29:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/04/AdobeStock_1059017397-Radioligand-Binding-Assay-RLBA-1920.jpg https://oncodesign-services.propulse.dev/cpt_ressource/metastasis-development-induced-by-intracarotid-injection/ 2025-04-29T18:00:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/novel-psma-and-fap-mouse-models/ 2025-04-28T04:00:15+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/cooperativity-the-missing-link-in-molecular-glue-discovery/ 2025-05-01T09:54:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/03/Design-sans-titre-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/debiopharm-and-oncodesign-services-launch-strategic-collaboration/ 2025-05-02T09:47:25+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/12/Banner-Drung-Hunter.jpg https://oncodesign-services.propulse.dev/cpt_ressource/teq103-a-novel-therapeutic-for-the-treatment-of-breast-cancer/ 2025-05-12T15:42:20+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-preclinical-models-for-microbiome-research-in-oncology-and-inflammatory-diseases/ 2025-05-13T12:56:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/WebinarMicrobiome_website_newspage.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-establishing-an-expert-network-for-your-radiopharmaceutical-drug-development-program/ 2025-05-13T12:58:58+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/WebinarMRT_website_newspage.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-better-optimize-an-oncology-drug-discovery-program/ 2025-05-13T13:05:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/03/ODS_Webinar_Oncology.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-oncology-and-immuno-oncology-precision-medicine-from-hit-finding-to-pre-clinical-candidate-selection/ 2025-05-13T13:09:39+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/BU-Service-Inpact-Inflammation-macrophage-Oncodesign.jpg https://oncodesign-services.propulse.dev/cpt_ressource/webinaire-fr-how-do-we-keep-you-in-the-race-of-covid-19/ 2025-05-13T13:22:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_website_Webinar_covid_19-stream.png https://oncodesign-services.propulse.dev/cpt_ressource/cancer-vaccine-toolbox-innovative-strategies-for-prophylactic-or-therapeutic-vaccines/ 2025-05-13T13:40:25+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_SiteWeb_Webinar-Vaccinev2.png https://oncodesign-services.propulse.dev/cpt_ressource/en-mri-going-beneath-the-surface-in-preclinical-oncology/ 2025-05-13T13:42:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2022/03/ODS_Webinar_Oncology.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-new-interactive-panel-webinar-drive-brothers-in-arms-to-support-small-molecule-drug-discovery-from-hit-to-ind/ 2025-05-13T13:44:25+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/11/visuel-oncologie.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-better-predict-your-drug-efficacy-to-combat-liver-diseases/ 2025-05-13T13:46:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_WEbinar_0207_Linkedin_Stream.png https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-assess-the-interplay-between-tumor-microbiota-and-therapies-a-comprehensive-platform-to-investigate-bacteria-as-immuno-modulating-vectors-or-agents/ 2025-05-13T13:49:30+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_WEbinar_Linkedin_25_juin_Stream.png https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-better-predict-the-effect-of-cancer-immunotherapy-tailored-made-humanized-mouse-models-are-the-key-solution-2/ 2025-05-13T13:52:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_WEbinar_Site_Web_CMI2020.png https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-recruit-immune-cells-against-tumor-bispecific-compounds-are-the-key-for-new-oncology-therapeutic-strategy/ 2025-05-13T13:54:25+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_WEbinar_Linkedin_Stream.png https://oncodesign-services.propulse.dev/cpt_ressource/en-simple-services-or-solutions-provider-what-is-the-best-option-to-support-your-drug-discovery-efforts-at-preclinical-stage/ 2025-05-13T13:59:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/WebinarMRT_website_newspage.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-how-to-trigger-the-immune-response-in-anti-tumor-therapy-a-comprehensive-in-vitro-to-in-vivo-screening-platform-to-identify-icd-inducers/ 2025-05-13T14:04:41+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/06/banner_siteweb_Webinar-AGA-Avril2020.png https://oncodesign-services.propulse.dev/cpt_ressource/webinar-hidden-potential-using-fragments-to-uncover-new-ligandable-sites-on-popular-targets/ 2025-05-14T07:09:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/C.jpg https://oncodesign-services.propulse.dev/cpt_ressource/pdx-derived-organoids-insights-into-cancer-stem-cells-and-metastasis/ 2025-05-19T11:55:43+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/pharmacological-evaluation-using-the-abylink-tm-regio-selective-conjugation-technology/ 2025-05-22T07:14:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/mtl-004-a-promising-new-therapeutic-for-post-resection-treatment-of-glioblastoma/ 2025-05-22T07:22:29+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/what-can-engineered-cells-tell-you-about-your-compound/ 2025-06-10T11:49:46+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/engineered_calls_render.jpg https://oncodesign-services.propulse.dev/cpt_ressource/rethinking-progress-in-endometriosis-treatment/ 2025-06-12T07:34:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/Histology-cystic-lesion-in-pelvic-adipose-tissue.png https://oncodesign-services.propulse.dev/cpt_ressource/unlock-the-full-potential-of-cancer-drugs-with-mrt-white-paper/ 2025-06-12T09:08:57+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/02/ODS-Dijon-Pharmaco-imaging-010-ratio-1-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/humanized-models-for-oncology-research-download/ 2025-06-18T17:02:59+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/04/Sans-titre-1200-x-628-px-8.jpg https://oncodesign-services.propulse.dev/cpt_ressource/translational-oncology-research-models-download/ 2025-06-19T08:59:35+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/04/Sans-titre-1200-x-628-px-8.jpg https://oncodesign-services.propulse.dev/cpt_ressource/webinar-humanized-mice-in-immuno-oncology-a-game-changer-for-preclinical-research/ 2025-06-27T13:13:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/Webinar-HIS-models-banner.jpg https://oncodesign-services.propulse.dev/cpt_ressource/advanced-64cu-67cu-based-theranostics/ 2025-07-01T13:43:17+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/02/ODS-Dijon-Pharmaco-imaging-010-ratio-1-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncology-cro-of-the-year-2025-france/ 2025-07-04T08:30:05+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/10/ODS-Team-Asterix.jpeg https://oncodesign-services.propulse.dev/cpt_ressource/radionuclides-a-sourcing-challenge/ 2025-07-15T13:29:36+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/09/banner-radionuclide_WebP-1-scaled.webp https://oncodesign-services.propulse.dev/cpt_ressource/webinar-bridging-species/ 2025-07-30T15:55:08+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/Webinar-HIS-models-banner.jpg https://oncodesign-services.propulse.dev/cpt_ressource/en-how-rodent-and-nhp-models-support-covid-19-treatment-development/ 2025-07-31T08:18:13+00:00 https://www.oncodesign-service.com/wp-content/uploads/2021/10/WebinarCOVID_website_newspage.jpg https://oncodesign-services.propulse.dev/cpt_ressource/oncology-drug-development-3d-cell-models/ 2025-07-31T08:50:32+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/08/Image1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/how-humanized-models-advance-oncology-drug-development/ 2025-08-01T11:19:37+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/laboratory-microscope-oncodesign.png https://oncodesign-services.propulse.dev/cpt_ressource/pdx-research-model-guide/ 2025-08-05T15:29:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/03/17.png https://oncodesign-services.propulse.dev/cpt_ressource/cdx-research-model-guide/ 2025-08-05T15:30:19+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/08/Oncology-CRO-of-the-Year-France-2024-2025-1.jpg https://oncodesign-services.propulse.dev/cpt_ressource/structural-biology-guide/ 2025-08-11T07:32:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/08/Molecular-Glue-Structure.jpg https://oncodesign-services.propulse.dev/cpt_ressource/covalent-compound-screening-guide/ 2025-09-01T14:47:00+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/08/Covalent-Crystal-Structure-1920.jpg https://oncodesign-services.propulse.dev/cpt_ressource/screening-covalent-compound-libraries/ 2025-09-09T12:57:51+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/09/Covalent-Compound-Warhead.jpg https://oncodesign-services.propulse.dev/cpt_ressource/webinar-how-to-maximize-cancer-drug-candidate-potential-through-molecular-radiotherapy/ 2025-09-16T07:44:28+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/Webinar-HIS-models-banner.jpg https://oncodesign-services.propulse.dev/cpt_ressource/poster-covalent-screening/ 2025-09-18T10:07:25+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/ebook-radiopharmaceutical-development-download/ 2025-10-01T13:54:26+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/09/Page-alpha-radioTx-2.webp https://oncodesign-services.propulse.dev/cpt_ressource/how-to-repurpose-your-cancer-drug-to-a-molecular-radiotherapy-drug-candidate/ 2025-10-03T08:41:21+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/12/Banner-Drung-Hunter.jpg https://oncodesign-services.propulse.dev/cpt_ressource/what-was-trending-at-eanm-2025/ 2025-10-16T09:18:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/10/Targeted-Radiotherapy-representation.jpg https://oncodesign-services.propulse.dev/cpt_ressource/when-breast-cancer-spreads-to-the-brain/ 2025-10-22T06:42:40+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Vignettes-ressources.jpg https://oncodesign-services.propulse.dev/cpt_ressource/poster-humanized-mice-in-immuno-oncology-a-game-changer-for-preclinical-research/ 2025-11-07T00:30:47+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/02/Poster-scientifique.jpg https://oncodesign-services.propulse.dev/cpt_ressource/establishing-a-lead212-radiotheranostic-approach/ 2025-11-20T11:06:56+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/11/Lead-theranostic-banner_11zon.jpg https://oncodesign-services.propulse.dev/cpt_ressource/precision-hit-discovery-strategies-for-complex-and-resistant-targets/ 2025-11-25T10:42:14+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/C.jpg https://oncodesign-services.propulse.dev/cpt_ressource/making-good-choices-in-preclinical-development/ 2025-11-26T14:58:42+00:00 https://www.oncodesign-service.com/wp-content/uploads/2024/01/47.jpg https://oncodesign-services.propulse.dev/cpt_ressource/advancing-the-3rs-in-drug-discovery-with-pharmaco-imaging/ 2025-12-09T15:47:24+00:00 https://www.oncodesign-service.com/wp-content/uploads/2023/12/Banner-Drung-Hunter.jpg https://oncodesign-services.propulse.dev/cpt_ressource/improving-predictivity-in-oncology-with-orthotopic-models/ 2025-12-11T11:06:01+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/06/Webinar-HIS-models-banner.jpg https://oncodesign-services.propulse.dev/cpt_ressource/preclinical-tools-to-advance-your-colitis-pipeline/ 2026-01-28T14:46:53+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/11/ODS-Paris.jpg https://oncodesign-services.propulse.dev/cpt_ressource/trt-and-oncological-drugs-acting-together/ 2026-01-28T15:12:16+00:00 https://www.oncodesign-service.com/wp-content/uploads/2025/10/Targeted-Radiotherapy-representation.jpg https://oncodesign-services.propulse.dev/cpt_ressource/predicting-clinical-success-in-preclinical-inflammatory-gut-disease-research/ 2026-01-29T09:32:33+00:00 https://www.oncodesign-service.com/wp-content/uploads/2026/01/AdobeStock_1850563425.jpeg